Mather Group, Llc. Alnylam Pharmaceuticals, Inc. Transaction History

Mather Group, Llc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Oct 20, 2025	BUY	$311.12 - $482.13 $4,355 - $6,749	14 New	14 $6,000
Q1 2025 Apr 25, 2025	BUY	$233.07 - $290.7 $1,864 - $2,325	8 Added 66.67%	20 $5,000
Q4 2024 Jan 24, 2025	BUY	$232.27 - $300.43 $1,393 - $1,802	6 Added 100.0%	12 $2,000
Q3 2024 Oct 07, 2024	SELL	$233.81 - $287.01 $935 - $1,148	-4 Reduced 40.0%	6 $1,000
Q2 2024 Jul 08, 2024	BUY	$143.31 - $247.0 $429 - $741	3 Added 42.86%	10 $2,000

Q1 2024 Apr 08, 2024	BUY	$146.51 - $198.2 $1,025 - $1,387	7 New	7 $1,000

918

117M

1.25M

1.49M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $55.3B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Mather Group, Llc., based on Form 13F filings with the SEC.

Stay updated on Mather Group, Llc. with notifications on news.